Physician profile
Mark D Baker
NPI 1952530594
$5,809.31
in general payments reported to CMS, 2019-2025
22 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $195 · 2021: $445 · 2022: $828 · 2023: $923 · 2024: $1,258 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,121.50 | 2019-2025 | Wegovy, Saxenda |
| Astrazeneca Pharmaceuticals Lp | $1,048.97 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $734.00 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $601.82 | 2021-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $350.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Madrigal Pharmaceuticals | $266.07 | 2024-2025 | Rezdiffra |
| Lilly USA, LLC | $265.61 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Daiichi Sankyo INC. | $230.23 | 2019-2024 | Injectafer |
| Abbvie INC. | $207.31 | 2019-2025 | |
| Abbott Laboratories | $167.18 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $165.05 | 2019-2020 | |
| Medtronic, INC. | $161.26 | 2024 | Symplicity G3 |
| Glaxosmithkline, LLC. | $123.72 | 2019 | |
| Amarin Pharma, INC. | $120.90 | 2019 | |
| Ucb, INC. | $60.94 | 2023-2024 | Nayzilam |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $43.82 | 2025 | Vivitrol |
| Paratek Pharmaceuticals, INC. | $41.66 | 2022-2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $33.83 | 2025 | Vaxelis, Gardasil 9, Rotateq |
| Boston Scientific Corporation | $18.39 | 2025 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.99 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.21 | 2025 | Rexulti |
| Grifols USA, LLC | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.